The Longitude Prize on ALS, initiative of Challenge Works, the Motor Neurone Disease Association and partners, is an international challenge prize offering £7.5 million GBP ($10 million USD) to incentivize the use of AI-based approaches for therapeutic discovery in treating amyotrophic lateral sclerosis (ALS), the most common form of motor neuron disease. This prize is part of the modern Longitude Prize series, following the previous prizes on Antimicrobial Resistance and Dementia.

The prize is open to organizations worldwide, including academic groups, companies, non-profits, and partnerships between these entities. Individuals are not eligible to apply. The program provides seed funding, expert support, and capacity-building for competitors, with the top prize awarded to the solution that demonstrates the greatest effectiveness.

The deadline for applications is December 3, 2025. To learn more, visit the webpage here.